This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
All You Need to Know About Bio-Rad (BIO) Rating Upgrade to Buy
by Zacks Equity Research
Bio-Rad (BIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
Phibro (PAHC) Down 3.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.25% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for April 19th
by Zacks Equity Research
ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
by Zacks Equity Research
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
by Zacks Equity Research
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Waters (WAT) Boosts Waters Operating Segment With HPLC System
by Zacks Equity Research
Waters (WAT) launches Alliance iS Bio HPLC system to improve efficiency across biopharma QC laboratories, boosting its Waters Operating segment.
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
by Zacks Equity Research
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Green Thumb Industries Inc. (GTBIF) Soars 11.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Green Thumb Industries Inc. (GTBIF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition
by Zacks Equity Research
Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down
by Zacks Equity Research
Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.
Bio-Rad Laboratories (BIO) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 5.80% and 0.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?
by Zacks Equity Research
Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.
3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024
by Riya Anand
Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.
Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes
by Zacks Equity Research
Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.
Why Is Phibro (PAHC) Up 13.6% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Zimmer (ZBH) Up 10.8% Since Last Earnings Report?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for On Bio-Rad Laboratories (BIO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bio-Rad Laboratories (BIO) stock based on the movements in the options market lately.
Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure
by Zacks Equity Research
Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.